Background
Methods
Patient population
Pretreatment evaluation
Laboratory examination
Treatment
Outcome and follow-up
Statistical analysis
Results
Patient characteristics
Characteristic | No. of patients (%) |
---|---|
Age, yr | |
Median | 45 |
Interquartile range | 38–53 |
Sex | |
Male | 1167 (75.3) |
Female | 383 (24.7) |
T stage | |
T1 | 190 (12.3) |
T2 | 265 (17.1) |
T3 | 796 (51.4) |
T4 | 299 (19.3) |
N stage | |
N0 | 190 (12.3) |
N1 | 928 (59.9) |
N2 | 226 (14.6) |
N3 | 206 (13.3) |
Overall stage | |
II | 332 (21.4) |
III | 754 (48.6) |
IVA-B | 464 (29.9) |
Family history | |
No | 444 (28.6) |
Yes | 1106 (71.4) |
Smoking history | |
No | 961 (62.0) |
Yes | 589 (38.0) |
Drinking history | |
No | 1358 (87.6) |
Yes | 192 (12.4) |
NLR | |
Median | 2.27 |
Interquartile range | 1.71–3.12 |
Chemotherapy | |
RT alone | 165 (10.6) |
CCRT | 594 (38.3) |
NACT+CCRT | 756 (48.8) |
CCRT+AC | 35 (2.3) |
The prognostic value of NLR in NPC
Endpoint | Variable | HR | 95% CI for HR | P value |
---|---|---|---|---|
OS | ||||
Age (≤ 45 vs. > 45) | 1.69 | 1.29–2.22 | < 0.001 | |
Sex (Male vs. Female) | 1.30 | 0.90–1.87 | 0.163 | |
Smoking history (No vs. Yes) | 1.11 | 0.83–1.49 | 0.492 | |
T stage (T1–2 vs. T3–4) | 1.34 | 0.98–1.85 | 0.071 | |
N stage (N0–1 vs. N2–3) | 2.86 | 2.19–3.73 | < 0.001 | |
NLR (≤ 2.50 vs. > 2.50) | 1.72 | 1.31–2.24 | < 0.001 | |
Treatment (RT alone vs CCRT) | 1.43 | 0.82–2.50 | 0.213 | |
Treatment (RT alone vs NACT+CCRT) | 1.23 | 0.70–2.14 | 0.472 | |
DMFS | ||||
Sex (Male vs. Female) | 1.34 | 0.95–1.90 | 0.097 | |
N stage (N0–1 vs. N2–3) | 3.50 | 2.65–4.63 | < 0.001 | |
NLR (≤ 2.50 vs. > 2.50) | 1.45 | 1.10–1.92 | 0.009 | |
LRFS | ||||
Age (≤ 45 vs. > 45) | 1.40 | 1.02–1.92 | 0.035 | |
N stage (N0–1 vs. N2–3) | 1.35 | 0.97–1.88 | 0.077 | |
PFS | ||||
Age (≤ 45 vs. > 45) | 1.44 | 1.16–1.79 | 0.001 | |
Family history (No vs. Yes) | 1.17 | 0.91–1.50 | 0.213 | |
Smoking history (No vs. Yes) | 1.12 | 0.90–1.39 | 0.323 | |
T stage (T1–2 vs. T3–4) | 1.27 | 0.99–1.62 | 0.063 | |
N stage (N0–1 vs. N2–3) | 2.25 | 1.81–2.79 | < 0.001 | |
NLR (≤ 2.50 vs. > 2.50) | 1.29 | 1.04–1.59 | 0.021 |
Endpoint | Variable | HR | 95% CI for HR | P value |
---|---|---|---|---|
OS | ||||
Age (≤ 45 vs. > 45) | 1.64 | 1.25–2.14 | < 0.001 | |
Sex (Male vs. Female) | 1.3 | 0.90–1.88 | 0.158 | |
Smoking history (No vs. Yes) | 1.09 | 0.82–1.46 | 0.553 | |
T stage (T1–2 vs. T3–4) | 1.42 | 1.04–1.94 | 0.029 | |
N stage (N0–1 vs. N2–3) | 2.84 | 2.18–3.69 | < 0.001 | |
DMFS | ||||
Sex (Male vs. Female) | 1.34 | 0.95–1.89 | 0.098 | |
N stage (N0–1 vs. N2–3) | 3.49 | 2.64–4.61 | < 0.001 | |
LRFS | ||||
Age (≤ 45 vs. > 45) | 1.4 | 1.02–1.92 | 0.035 | |
N stage (N0–1 vs. N2–3) | 1.35 | 0.97–1.88 | 0.077 | |
PFS | ||||
Age (≤ 45 vs. > 45) | 1.42 | 1.15–1.77 | 0.001 | |
Family history (No vs. Yes) | 1.17 | 0.92–1.50 | 0.205 | |
Smoking history (No vs. Yes) | 1.11 | 0.89–1.38 | 0.34 | |
T stage (T1–2 vs. T3–4) | 1.28 | 1.00–1.65 | 0.048 | |
N stage (N0–1 vs. N2–3) | 2.24 | 1.81–2.78 | < 0.001 |
NLR is associated with known prognostic clinical indices
No. of patients (%) stratified by NLR | |||
---|---|---|---|
Characteristic | ≤ 2.50 (n = 813) | > 2.50 (n = 737) | P value |
Age | 0.222 | ||
≤ 45 | 404 (49.7) | 343 (46.6) | |
> 45 | 409 (50.3) | 394 (53.4) | |
Sex | 0.034 | ||
Male | 575 (70.7) | 557 (75.6) | |
Female | 238 (29.3) | 180 (24.4) | |
T stage | 0.001 | ||
T1 | 110 (13.5) | 80 (10.9) | |
T2 | 151 (18.6) | 114 (15.5) | |
T3 | 418 (51.4) | 378 (51.3) | |
T4 | 134 (16.5) | 165 (22.4) | |
N stage | 0.015 | ||
N0 | 106 (13.0) | 84 (11.4) | |
N1 | 485 (59.7) | 443 (60.1) | |
N2 | 132 (16.2) | 94 (12.8) | |
N3 | 90 (11.1) | 116 (15.7) | |
Overall stage | < 0.001 | ||
II | 189 (10.9) | 143 (19.4) | |
III | 316 (38.9) | 341 (46.3) | |
IVA-B | 396 (48.7) | 253 (34.3) | |
Family history | 0.574 | ||
No | 575 (70.7) | 531 (72.0) | |
Yes | 238 (29.3) | 206 (28.0) | |
Smoking history | 0.402 | ||
No | 496 (61.0) | 465 (63.1) | |
Yes | 317 (39.0) | 272 (36.9) | |
Drinking history | 0.247 | ||
No | 720 (88.6) | 638 (86.6) | |
Yes | 93 (11.4) | 99 (13.4) | |
Treatment strategy | 0.779 | ||
RT | 89 (10.9) | 76 (10.3) | |
CCRT alone | 316 (38.9) | 278 (37.7) | |
NACT+CCRT | 408 (50.2) | 383 (52.0) |